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Background
Carnitine palmitoyltransferase (CPT) deficiencies are a
common autosomal recessive disorder resulting in a
defect in mitochondrial fatty acid oxidation. The CPT
system is made up of two separated proteins located in
the outer CPT1 and inner CPT2 mitochondrial mem-
branes. CPT1 catalyses the formation of acylcarnitine
from carnitine and long chain fatty acyl-CoA. Acylcarni-
tine then crosses the inner mitochondrial membrane
where it combines with CoA to form acyl-CoA, a pro-
cess catalyzed by CPT2. Acyl-CoA is then available to
undergo beta-oxidation. Deficiencies of both CPT1 and
2 have been described and leave patients unable to
derive energy from fatty acid oxidation. Once immediate
glucose and glycogen stores are exhausted, hypoglycemia
may occur. This process conducts to rhabdomyolysis
with muscle pains, hyperkalemia, metabolic acidosis and
myoglobinuria. In severe severe cases acute renal failure,
cardiac arrest and death ensure.
Case report
A 35 years old woman was referred for a consultation to
our malignant hyperthermia center before anesthesia for
in vitro fertilization treatment (IVF). She never had an
anesthesia. Her parents had 2 other healthy children. All
family’s members had had general anesthesia without
problems. At 18 year old, after massive rhabdomyolysis
during an interactive viral infection, the patient had a
DNA analysis that revealed 1237Arg and Ser113Leu,
mutations in CPT 2 gene. The patient’s was diagnosed
as CPT2 deficiency. From these date she over went 4
crises of massive rhabdomyolisis, during which the CPK
levels exceed 90.000 IU/l. The patient is in good physi-
cal status, renal functions are normal, liver enzymes are
mildly elevated.
Conclusions
1. Is there indication for muscle biopsy and in vitro
contracture test (IVCT)? What is the risk and what is
the benefit from IVCT?
2. Does this patient need a special genetic counseling
before pregnancy?
3. IVF needs a great number of sedations - what is the
sedation plan?
4. The pregnancy may aggravates her general status
and the delivery may be a challenge for patient as well
as for us - anesthesia plans.
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